It's almost exhausting watching BIOL do this every time...jump, fall, jump, fall, all right back to this channel. There's an interim gap to fill from a few weeks back but still many other levels to consider IF it can break back above and out of this channel. I think volume will be an indicator to watch in consideration of whether or not this can happen.
Because...
There's still a pretty big gap to fill from a few years ago but again, with a lot of biotech gaining recently, small caps could be back on the menu.
After Maxim Group upgraded SYN from a hold to a buy, shares of the biotech company dramatically increased. In addition to this, Maxim Group analysts gave a price target for SYN of $2.50. This represents a 10% or so...
ISR has been something of a sight in this market. Now, after pulling in and settling down a bit, it's back at the historic support/resistance level. With momentum acting as a tailwind in biotech stocks, overall, I'll be interested to see if it can get back above this level in more of a "calm fashion" haha.
While fewer surgeries occurred last year due to covid,...
INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement
$INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain...
Shares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday.
BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept...
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data
‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21
‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a...
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)
Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S.
$NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby...
$EYES Receives FDA Approval for the Argus 2s Retinal Prosthesis System
$EYES today announced U.S. FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company...
Just for fun Biotech trending with channels relative to XBI. Should normally continue Current 1Yr Channel (white) and entering Channel 'B' after been solidly rejected at top of it.
ASX:BIT Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus...
$TRIL Target 17.47 for 29.50%
Or next add at 9.51
I am not your financial advisor. My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk.
GL
INVO potential day trade. I may enter above the 5.85 for a price target of 7.45 on a bounce up from support. It appears that volume is concentrated at two primary levels, this trade attempts to profit on that spread.
(Just an idea, not advice)
A buddy of mine mentioned this when we spoke about "high conviction trades" My HCT is 3D printing. This is his. I took a look and it appears we're setting up for what appears to be a potential 5th wave of a leading diagonal. This in theory if it proves to be right, should kick off the first motive cycle. Right now it looks like it can go either way. If price...
Here is my follow up update on original CRSP swing short trade idea I put up on January 14th.
On this post, I am zooming out to weekly chart, looking at longer time frame to capture cyclical trends.
Going back all the way to 2017 inception period, the higher than average volatilities are pretty easy to notice. It moves up really fast but also coming down. Every...
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome.
Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product...
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement.
Corium expects to make AZSTARYS commercially available in the U.S. as early as the second...
